trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['destiny-breast03', 'breast', 'pivotal', 'daiichisankyous']
today at #asco22: we are presenting follow-up safety data from the pivotal destiny-breast03 phase 3 trial in patients with #her2 positive metastatic #breastcancer. 
Daiichi Sankyo US’s channel featuring our biopharmaceutical news, passion for innovation & compassion for patients.  See our guidelines: https://t.co/4iEAbpw1Wx